Biome Australia Limited (BIO.AX)
AUD 0.57
(4.63%)
AUD 0.57
(4.63%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 1.3 Million AUD | 13.16% |
| 2023 | 1.14 Million AUD | 145.29% |
| 2022 | 467.04 Thousand AUD | 476.6% |
| 2021 | 81 Thousand AUD | -83.95% |
| 2020 | 504.53 Thousand AUD | 1093.23% |
| 2019 | 42.28 Thousand AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.34 Million AUD | 188.42% |
| 2024 Q4 | 1.3 Million AUD | 0.0% |
| 2024 FY | 1.3 Million AUD | 13.98% |
| 2024 Q2 | 1.45 Million AUD | 7.7% |
| 2023 Q2 | 422.43 Thousand AUD | 29.24% |
| 2023 FY | 1.14 Million AUD | 145.29% |
| 2023 Q3 | 1.04 Million AUD | 147.62% |
| 2023 Q1 | 326.85 Thousand AUD | -30.02% |
| 2023 Q4 | 467.04 Thousand AUD | -55.35% |
| 2022 Q2 | 492.12 Thousand AUD | 16.5% |
| 2022 FY | 467.04 Thousand AUD | 476.6% |
| 2022 Q4 | 467.04 Thousand AUD | 24.43% |
| 2022 Q3 | 375.34 Thousand AUD | -23.73% |
| 2022 Q1 | 422.42 Thousand AUD | 425.3% |
| 2021 Q4 | 80.41 Thousand AUD | 0.0% |
| 2021 Q3 | 80.41 Thousand AUD | 0.0% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 81 Thousand AUD | -83.95% |
| 2020 FY | 504.53 Thousand AUD | 1093.23% |
| 2019 FY | 42.28 Thousand AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 123.85 Thousand AUD | -954.223% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 5.65 Million AUD | 76.904% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 689.69 Thousand AUD | -89.319% |
| Imugene Limited | 1.54 Million AUD | 15.593% |
| Noxopharm Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 1.11 Million AUD | -17.337% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | 330.48 Thousand AUD | -295.091% |
| Proteomics International Laboratories Limited | 316.39 Thousand AUD | -312.686% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 18.24 Billion AUD | 99.993% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | -48.414% |
| Starpharma Holdings Limited | 3.52 Million AUD | 62.99% |
| Nanollose Limited | 42.53 Thousand AUD | -2970.113% |
| Memphasys Limited | 4.41 Million AUD | 70.413% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 1.56 Million AUD | 16.392% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 421.96 Thousand AUD | -209.436% |
| Race Oncology Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.44 Million AUD | 92.515% |
| Dimerix Limited | 149.68 Thousand AUD | -772.323% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 1.22 Million AUD | -6.306% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 159.04 Thousand AUD | -720.975% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 1.48 Million AUD | 12.191% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | 7130.00 AUD | -18213.029% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| AdAlta Limited | 2.49 Million AUD | 47.657% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 23.59 Thousand AUD | -5434.584% |
| Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | -445.573% |
| Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | -60.963% |
| Avecho Biotechnology Limited | 175.15 Thousand AUD | -645.482% |
| Actinogen Medical Limited | 319.06 Thousand AUD | -309.228% |
| Immuron Limited | 173.49 Thousand AUD | -652.589% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |